Home ›
NPI 1770659732
NPI deactivated
1770659732
1770659732 was paid $209K by Medicaid between Jan 2018 and Mar 2023, across 49 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 54% of everything it billed.
33Billing provider info1770659732
33aNPI1770659732
33bProvider type—
28Total paid$209K
24GClaims25,024
24DCodes billed49
24AFirst – last monthJan 2018 – Mar 2023
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,009 | $86K | |
| 2019 | 12,273 | $83K | |
| 2020 | 2,561 | $38K | |
| 2021 | 91 | $2K | |
| 2022 | 52 | $0.00 | |
| 2023 | 38 | $63.61 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 54% | 4,061 | 3,019 | $112K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 32% | 2,603 | 2,112 | $67K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 5.6% | 1,540 | 1,271 | $12K |
| 3008F | <1% | 1,520 | 1,149 | $2K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 620 | 497 | $2K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 569 | 489 | $2K |
| 1160F | <1% | 1,469 | 1,123 | $1K | |
| 1159F | <1% | 1,463 | 1,116 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 201 | 93 | $1K |
| 3074F | <1% | 980 | 746 | $1K | |
| 3078F | <1% | 898 | 664 | $982.40 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 45 | 40 | $904.99 |
37 more codes
| 1125F | <1% | 1,189 | $840.00 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,206 | $804.60 |
| 90674 | <1% | 67 | $513.56 | |
| 3079F | <1% | 303 | $450.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 59 | $335.40 |
| 3077F | <1% | 198 | $330.00 | |
| 82948 | <1% | 381 | $317.50 | |
| 81001 | <1% | 274 | $304.61 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 35 | $294.53 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 48 | $279.64 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 15 | $262.15 |
| 92551 | <1% | 35 | $229.24 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 231 | $213.91 |
| 90688 | <1% | 29 | $200.91 | |
| 3075F | <1% | 72 | $170.00 | |
| 1126F | <1% | 132 | $150.00 | |
| 81025 | <1% | 55 | $136.94 | |
| 3080F | <1% | 53 | $130.00 | |
| 99173 | <1% | 54 | $95.38 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 91 | $88.21 |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 25 | $63.20 |
| 80305 | <1% | 16 | $57.64 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 135 | $33.09 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 34 | $24.58 |
| G0008 | Administration of influenza virus vaccine | <1% | 12 | $15.42 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 1,247 | $0.00 |
| G8755 | Most recent diastolic blood pressure >= 90 mmhg | 0% | 14 | $0.00 |
| G9664 | Patients who are currently statin therapy users or received an order (prescription) for statin therapy | 0% | 140 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 42 | $0.00 |
| 80502 | 0% | 16 | $0.00 | |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 147 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 397 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 432 | $0.00 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 1,171 | $0.00 |
| G8506 | Patient receiving angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy | 0% | 17 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 589 | $0.00 |
| G8731 | Pain assessment using a standardized tool is documented as negative, no follow-up plan required | 0% | 94 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.